Resultat for sygdomsaktivitet I alle tre forsøg, øgede rituximab 2 x 1000 mg signifikant andelen af patienter, der opnåede mindst 20% forbedring i ACR score, sammenlignet med patienter behandlet med methotrexat alene (tabel 7).
Disease activity outcomes In all three studies, rituximab 2 x 1000 mg significantly increased the proportion of patients achieving at least a 20% improvement in ACR score compared with patients treated with methotrexate alone (Table 7).